Published in final edited form as:
Mol Pharm. 2006 ; 3(6): 717–725.

Pharmacokinetic and Biodistribution Studies of a Bone-targeting Drug Delivery System Based on *N*-(2-Hydroxypropyl) methacrylamide (HPMA) Copolymers

Dong Wang^{1,4}, Monika Sima¹, R. Lee Mosley⁵, Jasmine P. Davda⁴, Nicole Tietze^{1,ξ}, Scott C. Miller³, Peter R. Gwilt⁴, Pavla Kopečková¹, and Jindřich Kopeček^{1,2,*}

¹Department of Pharmaceutics and Pharmaceutical Chemistry/CCCD, University of Utah, Salt Lake City, Utah 84112, USA

²Department of Bioengineering, University of Utah, Salt Lake City, Utah 84112, USA

³Division of Radiobiology, University of Utah, Salt Lake City, Utah 84112, USA

⁴Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA

⁵Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA

Abstract

Osteotropicity of novel bone-targeted HPMA copolymer conjugates has been demonstrated previously with bone histomorphometric analysis. The pharmacokinetics and biodistribution of this delivery system were investigated in the current study with healthy young *BALB/c* mice. The ¹²⁵I-labeled bone-targeted and control (non-targeted) HPMA copolymers were administered intravenously to mice and their distribution to different organs and tissues were followed using a gamma counter and single photon emission computed tomography (SPECT). Both the invasive and non-invasive data further confirmed that the incorporation of D-aspartic acid octapeptide (D-Asp₈) as bone-targeting moiety could favorably deposit the HPMA copolymers to the entire skeleton, especially to the high bone turnover sites. To evaluate the influence of molecular weight, three fractions (*M_w* of 24, 46, and 96 kDa) of HPMA copolymer – D-Asp₈ conjugate were prepared and evaluated. Higher molecular weight of the conjugate enhanced the deposition to bone due to the prolonged half-life in circulation, but it weakened the bone-selectivity. A higher content of bone-targeting moiety (D-Asp₈) in the conjugate is desirable to achieve superior hard tissue selectivity. Further validation of the bone-targeting efficacy of the conjugates in animal models of osteoporosis and other skeletal diseases is needed in the future.

Keywords

bone-targeting; drug delivery; HPMA copolymer; SPECT; pharmacokinetics; biodistribution

* Corresponding author: Jindřich Kopeček, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 30 S. 2000 E. Rm. 201, Salt Lake City, Utah 84112–5820, USA; Phone: (801) 581–7211; Fax: (801) 581–7848. E-mail: Jindrich.Kopecek@utah.edu.
ξCurrent address: Pharmaceutical Biology-Biotechnology, Department of Pharmacy, Butenandtst. 5–13, Munich, Germany.

SUPPORTING INFORMATION Movies 1 and 2 of tomographic analysis (with SPECT) of Tyr-D-Asp₈'s distribution in the skeleton can be obtained free of charge at <http://pubs.acs.org>.

INTRODUCTION

The worldwide increase of human life span is accompanied by a heavy socioeconomic burden of widespread musculoskeletal diseases and their substantial morbidity and mortality. Currently, 44 million Americans, or 55 percent of the people 50 years of age and older, are in danger of having osteoporosis; 10 million individuals probably already have the disease.^{1,2} Similarly, arthritis, such as rheumatoid arthritis and osteoarthritis, which is always accompanied by skeletal complications, also affect tens of millions of American lives.³⁻⁵

However, the advancement of biomedical research in the past few decades has dramatically improved our understanding of these diseases. Many molecular targets have been identified and numerous new therapeutic agents have been developed for the treatment of musculoskeletal diseases.⁶ In addition, novel concepts in drug delivery technologies have also been developed in an attempt to enhance osteotropicity of drugs and to improve their pharmacokinetic profile and therapeutic efficacy.⁷

Recently, we have developed a polymeric bone-targeting drug delivery system based on *N*-(2-hydroxypropyl)methacrylamide (HPMA) copolymer.^{8,9} Alendronate (a bisphosphonate) and D-aspartic acid octapeptide (D-Asp₈) have been introduced as targeting moieties, which could favorably recognize and strongly bind to biomineral (e.g. carbonated hydroxyapatite (HA) or HA in bone) surfaces. Initial *in vitro* evaluation supported this hypothesis; > 60 % of binding to artificial HA particles was observed with targeted HPMA copolymers.⁸ Similar data were obtained in preliminary studies *in vivo*. Injection of the delivery system to young *BALB/c* mice did not show signs of any obvious adverse events. Histomorphometric analyses of the long bones (tibia and femur) isolated from the animals demonstrated very strong accumulation of the targeted HPMA copolymers at the high bone turnover sites, such as metaphyseal spongiosa, and moderate deposition at sites of slower turnover, such as endosteum and periosteum of diaphyseal shaft. In our most recent study, it was found that by incorporating different bone-targeting moieties, the delivery system could effectively differentiate bone formation surface from resorption surface, with D-Asp₈ preferentially binding to authentic bone resorption surfaces.¹⁰ As the first model drug tested, prostaglandin E₁ (PGE₁, bone-anabolic agent) has also been incorporated into the delivery system via a cathepsin K-specific peptide linker (Gly-Pro-Nle). Effective release of intact PGE₁ from the delivery system was observed in the presence of cathepsin K (an osteoclast-specific enzyme).⁹

In the current study, we report the first systemic pharmacokinetic and biodistribution (PK/BD) study of the HPMA copolymer-based bone-targeting delivery system on healthy young *BALB/c* mice.

EXPERIMENTAL SECTION

Materials

N-(2-hydroxypropyl)methacrylamide (HPMA),¹¹ *N*-methacryloylaminopropyl fluorescein thiourea (MA-FITC),¹² *N*-methacryloylglycylglycine (MA-Gly-Gly-OH),¹³ and *N*-methacryloyltyrosineamide (MA-Tyr-NH₂)¹⁴ were prepared as described previously. Sephadex G-25 and LH-20 resins were obtained from GE HealthCare (Piscataway, NJ). 2-Chlorotriyl chloride resin (100–200 mesh), *N*- α -Fmoc-D-aspartic acid α -t-butyl ester (Fmoc-D-Asp-OtBu), benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP®) and 1-hydroxybenzotriazole hydrate (HOBt) were all purchased from Novabiochem (La Jolla, CA). Unless specified otherwise, all other reagents and solvents were purchased from Aldrich (Milwaukee, WI).

Characterization of the synthetic products

The weight average molecular weight (M_w) and number average molecular weight (M_n) of copolymers were determined by size exclusion chromatography (SEC) using the ÄKTA FPLC system (GE HealthCare) equipped with UV and RI detectors. SEC measurements were carried out on Superose 12 columns (HR 10/30) with PBS (pH = 7.3) as the eluent. The average molecular weights of the polymers were calculated using calibrations with narrow fractions of poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA).

UV spectra of compounds were obtained on a Cary 400 Bio UV-Visible spectrometer (Varian).

^1H NMR spectra of all synthesized compounds were recorded on a Varian Unity 500 MHz NMR spectrometer. The solvent peak was used for reference (d_6 -DMSO, 2.49 ppm).

Mass spectra of all synthesized compounds were obtained using a Finnigan LCQ DECA Mass Spectrometer interfaced to an ESI source.

To determine the content of D-Asp₈ peptide content in the copolymers, amino acid analyses of the polymer conjugates were fully hydrolyzed, phthalic dicarboxaldehyde (OPA)-derivatized and analyzed by a HPLC system. The amount of D-Asp₈ was calculated by calibration with standard D-Asp.

Synthesis of peptides

N-methacryloylglycylglycyl-(D-aspartic acid)₈ (MA-Gly-Gly-D-Asp₈) was synthesized by manual solid phase peptide synthesis (SPPS) using Fmoc/tBu strategy on 2-chlorotriyl chloride resin.¹⁵ After the attachment of the eighth D-aspartic acid residue onto the resin, MA-Gly-Gly-OH was coupled to the N-terminus of the resin-bound peptide with the similar PyBOP® coupling procedure. The peptide product was cleaved from the resin with TFA and was then precipitated into ether, dialyzed and lyophilized to obtain the final product. Its purity and structure was confirmed with MALDI-TOF mass spectrometry and amino acid analysis. Tyr-D-Asp₈ was also synthesized using a similar method.

Synthesis of HPMA copolymers containing D-Asp₈ and Tyr

HPMA copolymers were prepared by radical copolymerization of HPMA (100 mg, 0.7 mmol), MA-Tyr-NH₂ (4.2 mg, 0.015 mmol), MA-Gly-Gly-D-Asp₈ (63 mg, 0.06 mmol) in water/DMSO (2:1) using 4,4'-azobis(4-cyanopentanoic acid) (ACA, 12 mg, 0.06 mmol) as the initiator. MPA (3-mercaptopropionic acid; 1 μL) was used as the chain transfer agent to control the molecular weight. The mixture was polymerized in a sealed ampoule under nitrogen at 50 °C for 24 h. The polymer was purified by dialysis (MWCO 6–8 kDa) and isolated by lyophilization (147 mg, M_w = 67 kDa). The sample was fractionated on a Superose 12 column to produce narrow fractions with M_w of 24 kDa and 47 kDa. Similarly, a sample of M_w = 200 kDa was prepared; its fractionation produced a narrow fraction with M_w of 96 kDa. Control HPMA copolymers (no peptide) were synthesized following the same protocol.

The content of D-Asp₈ was determined by amino acid analysis, the content of Tyr by UV spectrophotometry.

The copolymers and Tyr-D-Asp₈ were radioiodinated (^{125}I) with a standard Chloramine-T assay¹⁴ and purified with Sephadex G-25 columns.

Animal studies

Invasive PK/BD study—All animal experiments were performed according to the University of Utah and University of Nebraska Medical Center IACUC approved

protocols. ^{125}I -labeled HPMa copolymers and Tyr-D-Asp₈ peptide (0.05–0.1 μCi) were administered to BALB/c mice (~ 20 g, 5–6 mice/group) via tail vein injection. Animals were sacrificed at designated time points and blood samples were withdrawn via the caudal vena cava. Major organs such as heart, lungs, kidneys, liver, spleen and long bones (tibia & femur, $\times 2$) were isolated, processed and counted with a gamma counter (Packard, Minaxi γ , Auto-gamma^R 5000 series, calibrated with Cs-137 nominally 0.25 μCi). The dose in blood was corrected according to the body weight of the animal.

Single photon emission computed tomography (SPECT) procedure—An animal SPECT (A-SPECT, Gamma Medica) was used to non-invasively investigate the distribution of the bone-targeting delivery system *in vivo*. ^{125}I -labeled polymers and peptide (10–20 μCi , in 200 μL saline) were given to mice (3/group) via tail vein injection and planar images of 15 sec exposure were acquired every 10 – 15 min for 2 h. Twenty-four hours after the injection, the animals were anesthetized with ketamine and xylazine and planar images were acquired with 1 min exposures. In order to obtain the tomographic images, the animals were put into a custom animal holder including fixed locations for placement of three aqueous radiolabeled fiducial markers offset in all three dimensions, stereotactic ear-bars and bite-bar. For each subject, 64 1-min exposures were acquired at equiangular points around a 360° rotation. Images were reconstructed with digital image analysis software provided by the manufacturer.

Pharmacokinetic analysis

Blood concentration-time profiles for each animal group were evaluated by compartmental analysis using WinNonlin software (version 3.2, Pharsight Corporation, Mountain View, CA). The pharmacokinetic parameters such as total clearance (CL), mean residence time (MRT), steady-state volume of distribution ($V_{d_{ss}}$), and biological half-life ($T_{1/2}$) were calculated from standard equations using WinNonlin. The area under the blood concentration–time curve (AUC) was calculated using the trapezoidal rule.

Statistical Analysis

One-way ANOVA test was used to determine statistical significance of the differences in the organ deposition among the different molecular weight P-D-Asp₈ conjugates. Student's unpaired *t*-test was used to determine statistical significance of the differences in the organ deposition between unconjugated and conjugated polymers of different molecular weights at 24 h. $P < 0.05$ was considered statistically significant.

RESULTS

Synthesis and characterization of conjugates

The structure of copolymers is shown in Figure 1 and the physicochemical characterization of all conjugates used in this study is summarized in Table 1. The fractionation of the copolymers was efficient; all polymer conjugates (fractions) showed narrow polydispersity (~ 1.1). Consequently, the impact of sample heterogeneity on the pharmacokinetic (PK) and biodistribution (BD) parameters was minimal. The contents of D-Asp₈ in the fractionated conjugates, however, were slightly different in spite of using the same copolymerization feed ratio. The conjugate fraction with the lowest molecular weight contained the highest amount of D-Asp₈. Chemical heterogeneity of copolymers prepared by radical copolymerization to high conversions is a frequently observed phenomenon. All copolymers contained a small amount (~ 2 mol%) of tyrosineamide moieties to permit radioiodination and detect their fate after intravenous administration to mice.

Biodistribution of the bone-targeting moiety (Tyr-D-Asp₈) and of HPMA copolymer-D-Asp₈ conjugates

The results of body distribution of HPMA copolymer conjugates and controls are shown in Figure 2. P-D-Asp₈ (with different M_w) and the targeting moiety (Tyr-D-Asp₈) were all very rapidly recognized by the skeleton (represented by tibia and femur). This occurred within just 15 min following the administration of the conjugates. The deposition of D-Asp₈ and P-D-Asp₈ (25 kDa) reached maximum levels in the long bones within the first 15 min, while the accumulation of P-D-Asp₈ (46 kDa) and P-D-Asp₈ (96 kDa) increased gradually during the experimental time frame. After 24 h, the amount of P-D-Asp₈ (96 kDa) in long bones was the highest (10.76 ± 0.37 % of the injected dose per gram of tissue), followed by Tyr-D-Asp₈ (4.25 ± 0.26 % of the injected dose per gram of tissue) and P-D-Asp₈ (46 kDa) (3.84 ± 0.79 % of the injected dose per gram of tissue); the lowest accumulation at 24 h was observed, as expected, with P-D-Asp₈ (24 kDa) (0.92 ± 0.08 % of the injected dose per gram of tissue).

While the analysis of isolated tibia and femur provided representative skeleton deposition data of the conjugates, the non-invasive SPECT imaging provided a more comprehensive understanding of their distribution pattern in the whole skeleton. As shown in Figure 3, the deposition sites of the conjugates, and especially of the (free) targeting moiety in the long bones were mainly the knee joints. On the other hand, the long bone shaft, where the bone marrow resides, only showed a weak signal of radioactivity. Other skeleton sites, such as the spine (including lumbar vertebrae), skull (including mandible and incisor roots of the rodents), and ribs were all detected with different levels of P-D-Asp₈ or Tyr-D-Asp₈ deposition. Among all the tested compounds, Tyr-D-Asp₈ demonstrated a pattern of exclusive deposition to the skeleton with minimal accumulation in the soft tissue. Tomographic imaging of the mice injected with the targeting moiety (24 h after administration, see Movie 1 and Movie 2 in supporting information) suggested that the peptide located mainly in the distal femur and proximal tibia and not in the joint cavity. For the deposition in the upper body, it was determined that the upper incisor root showed the highest deposition of the peptide, followed by lower incisor root, and mandible (Figure 3).

All bone-targeting polymer conjugates tested showed different levels of distribution to soft tissues (kidneys, liver, heart, etc., Figure 2). The detected differences were statistically significant ($p < 0.05$) among all P-D-Asp₈ conjugates tested at all time points except those of 24 kDa and 46 kDa in the kidneys and bone at 1 h. The distribution of P-D-Asp₈ (24 kDa) and Tyr-D-Asp₈ to most of the organs was transient and declined to a very low level in a few hours except in kidneys. Interestingly, Tyr-D-Asp₈ (1.1 kDa) showed a slightly higher uptake in most organs (except kidneys) at the end of 24 h when compared to P-D-Asp₈ (24 kDa). The administration of higher molecular weight P-D-Asp₈ (46 kDa) demonstrated an immediate high deposition to all organs examined, with the highest injected dose per gram of tissue (6.07 ± 0.26 %) found in the lung. The clearance of this polymer was slower than P-D-Asp₈ (24 kDa). At the end of 24 h, it showed a higher deposition in all organs when compared to P-D-Asp₈ (24 kDa) and Tyr-D-Asp₈. P-D-Asp₈-Tyr (96 kDa), the highest molecular weight bone-targeting copolymer, rapidly (within 15 min) distributed to all soft organs to very high levels with the lungs showing the highest injected dose per gram of tissue (12.69 ± 0.55 %). Although the amount of polymer deposited to the heart, lungs and kidneys gradually decreased, the levels in liver and spleen remained almost constant at the end of 24 h. The above biodistribution data are in agreement with the SPECT imaging results (Figure 3), which show little deposition of the ¹²⁵I-labeled P-D-Asp₈ (24 kDa) and Tyr-D-Asp₈ in all organs at 24 h except kidneys for P-D-Asp₈ (24 kDa). Large deposition of P-D-Asp₈ (46 kDa) in the liver is clearly evident at 24 h in the SPECT images. Strong signals in bladder and urinary track are also evident for this conjugate. But they may overlap with the signal from its deposition in spine. The SPECT of P-D-Asp₈ (96 kDa) was not performed due to the extremely high dose of the conjugate in

circulation. That may result in high background, making the identification of different organs difficult.

All tested compounds showed quick distribution to the kidneys. They were significantly cleared from the kidneys by the end of 24 h except P-D-Asp₈-Tyr (24 kDa), which seems to be exceptionally slow in clearing from the kidneys as compared to other organs. This result was echoed by the SPECT imaging of the animals injected with P-D-Asp₈ (24 kDa), in which the kidney demonstrated the highest signal level (Figure 3). However, it was not possible to distinguish whether the signal was from the cortex, medullar or pelvis of the kidneys.

For both P-D-Asp₈ conjugates (24 kDa and 46 kDa), the SPECT images (Figure 3) also indicated significant deposition in the bladder and urinary tract of some animals. However, this observation was not consistent in all animals imaged.

The distribution of control HPMA copolymers (no targeting peptide, P_{control}) was also evaluated at 24 h (Figure 2F). The accumulation in the bone was significantly higher ($p < 0.05$) for all three P-D-Asp₈ conjugates as compared to their respective P_{control} polymers. The distribution of low molecular weight P-D-Asp₈ and P_{control} (24 kDa and 22 kDa) to the soft organs was negligible except in the kidneys, where both polymers showed a deposition level of less than 1 % injected dose per gram of tissue. The deposition of P-D-Asp₈ (24 kDa) to the long bones, however, was more than 10 fold higher than that of P_{control} (22 kDa). For the medium sized copolymers, P-D-Asp₈ (46 kDa) demonstrated a lower deposition to all tissues tested than P_{control} (42 kDa), except long bones, where P-D-Asp₈ (46 kDa) showed a more than 2 fold higher deposition than P_{control} (42 kDa). For the high molecular weight copolymers tested, the bone-targeted P-D-Asp₈ (96 kDa) showed more than 4 fold higher deposition to long bones than P_{control} (105 kDa). P-D-Asp₈ (96 kDa) also showed significantly higher deposition to liver and spleen than P_{control} (105 kDa), while the latter showed slightly higher deposition to the lungs and kidneys. Thus, the targeting strategy did not result in higher accumulation ($p > 0.05$) in any of the soft organs with any of the different molecular weight conjugates except for P-D-Asp₈ (96 kDa) (in the liver and spleen).

Pharmacokinetic analysis of the tested conjugates in blood

The levels of the tested conjugates in the blood can be described in two groups. P-D-Asp₈ (24 kDa) and Tyr-D-Asp₈ both showed very low levels in the blood even at 15 min post administration, with Tyr-D-Asp₈ showing a higher concentration of 2.22 ± 0.27 % of the injected dose. The levels of both compounds rapidly declined to less than 0.5 % of the injected dose. On the other hand, both P-D-Asp₈ (46 kDa) and P-D-Asp₈ (96 kDa) showed very high initial levels in blood (15.76 ± 0.76 % and 34.87 ± 3.61 % of the injected dose, respectively) followed by a gradual decline. At the end of 24 h, only 0.54 ± 0.08 % of the administered P-D-Asp₈ (46 kDa) dose remained in blood while a much higher level was detected (11.10 ± 2.47 %) for P-D-Asp₈ (96 kDa).

Figure 4 illustrates the blood clearance of HPMA copolymer conjugates. A two-compartment model with i.v. bolus input best described the blood concentration-time data for all the groups. The pharmacokinetic parameters obtained for each group are summarized in Table 2. The elimination half-lives ($T_{1/2}$) of the three HPMA copolymer conjugates showed a strong correlation to molecular size, with the smallest copolymer demonstrating the shortest half-life (8.7 h). Assuming elimination is facilitated primarily by renal filtration, the larger molecular weight copolymers would be removed from the body at a much slower rate than the smaller ones, as reflected by the long half-life observed for the 96 kDa conjugate. Furthermore, the distribution of the 96 kDa conjugate appeared to be almost entirely restricted to the blood compartment as reflected by the low steady-state volume of distribution (V_{dss}). By contrast, the copolymer conjugate with the smallest molecular weight, 24 kDa, had a pronounced

distribution phase, reflecting rapid initial tissue uptake. The targeting moiety Tyr-D-Asp₈ shared disposition characteristics most closely with the conjugate possessing the lowest molecular weight, P-D-Asp₈ (24 kDa), as reflected in similar pharmacokinetic parameters, i.e., relatively high clearance and volume of distribution.

DISCUSSION

HPMA copolymer is a biocompatible water-soluble polymer that has been widely used as a drug carrier in cancer chemotherapies.^{16,17} Different targeting moieties have been conjugated with HPMA copolymer to improve their tissue specificity. The incorporation of alendronate and D-Asp octapeptide into HPMA copolymers has imparted the versatile delivery system a new ability of targeting to the skeleton.⁸ The histology findings are very encouraging, but the information they provide is limited. In the present PK/BD study of the bone-targeting HPMA copolymer conjugates with D-Asp₈ as targeting moiety, we designed the experiments to answer the following critical questions. (a) How efficient is the delivery system in targeting the whole skeleton? (b) What is the delivery system's sub-skeleton distribution pattern? (c) What is the prediction of its *in vivo* safety profile? (d) What can be done to further optimize the delivery system?

Both the invasive biodistribution study and the non-invasive SPECT imaging data support the effective targeting of D-Asp₈ and its copolymer conjugates to the skeleton. As can be seen in Figure 2, at the end of 24 h, the deposition of Tyr-D-Asp₈ into tibia and femur was the highest among all the organs and tissues evaluated. The SPECT imaging (Figure 3) indicated that such favorable binding was not limited to the long bones, as the peptide was also found in all the other parts of the skeleton, suggesting Tyr-D-Asp₈ is indeed a very powerful bone-targeting moiety.

Conjugation of D-Asp₈ to HPMA copolymers imparts the bone-targeting ability to the conjugates. As shown in Figures 2 and 3, all three bone-targeting conjugates showed strong binding to the tibia and femur. Compared to non-targeted HPMA copolymers (P_{control}), the preference of the D-Asp₈ containing polymeric delivery systems for the skeleton was pronounced. For P-D-Asp₈ (24 kDa), the binding to bones plateaus after 15–30 min. But the accumulation of P-D-Asp₈ (46 kDa) and P-D-Asp₈ (96 kDa) increased gradually during the 24 h, with P-D-Asp₈ (96 kDa) showing the highest deposition to bone. This observation may possibly be attributed to the different half-lives of the conjugates in circulation. As shown in Table 2, the half-lives in the first phase (α T_{1/2}) are solely dependent on the molecular weight of the compounds. The lower the molecular weight, the faster their distribution into the organs and tissues from the blood compartment and consequently, shorter their half-lives. On the other hand, the half-lives for the second phase (β T_{1/2}) basically followed the same trend, except Tyr-D-Asp₈. Possibly, the binding of the peptide to plasma proteins may have contributed to its extended stay in blood. However, this does not seem to have an impact on Tyr-D-Asp₈ binding to bones, as it plateaus 15 min post injection.

Apparently, the deposition of the bone-targeting delivery system to the skeleton is decided by two competing processes: (a) Distribution and binding to the bone surface, and (b) elimination from the blood via kidneys. While Tyr-D-Asp₈ has the advantages of fast tissue distribution and strong bone binding, P-D-Asp₈ (96 kDa) may benefit from its long residence time in the circulation and redistribution of the bone-targeting polymer from soft tissues to the hard tissue. Indeed, P-D-Asp₈ (96 kDa) showed the highest bone accumulation 24 h post administration. However, the non-specific accumulation of this polymer to soft tissues was also significantly higher than that of the other polymers (Figure 2E). Due to this unfavorable target-to-background ratio, the use of the very high MW polymer may not be the best option in improving the therapeutic index of the delivery system.

Among all the tested compounds, P-D-Asp₈ (24 kDa) showed the lowest deposition to the bone. Potentially, this is because it is denied of either of the advantages discussed above. The PK analysis data in Table 2 also agrees with previous *findings*¹⁸ suggesting a 45 kDa glomerular filtration cutoff size for HPMA copolymers. Those with molecular weight larger than this limit would have a much longer half-life in the blood compartment.

The SPECT results revealed that the delivery system might favorably deposit all over the skeleton. Our previous histomorphometric study of long bones only provided information about deposition of the delivery system in long bones.^{8,10} The current SPECT study indicated that the distribution of the HPMA copolymer-based delivery system was more favorable than initially anticipated. For Tyr-D-Asp₈, deposition was found in the knees, the spine (especially lumbar vertebrae), the ribs, and the skull. Tomographic analysis further clarified that the signals in the knees originated from the proximal tibia and distal femur. These findings agreed very well with previous histomorphometric results in which the metaphyseal spongiosa and cortex were heavily labeled but the cortical surfaces of the diaphyseal shaft were only lightly labeled.^{8,10} Tomographic analysis also clarified that the signals in the skull originate from the incisor roots and mandible of the animal. From the SPECT images, it is clear that both P-D-Asp₈ (24 kDa) and P-D-Asp₈ (46 kDa) demonstrated a pattern of deposition to the skeleton similar to Tyr-D-Asp₈, though not as selective. These findings are of great significance because in this animal model, all the skeletal sites mentioned above are high bone turnover sites featuring abundant blood supply. This observation suggests that this delivery system may become a very effective tool for the treatment of cancer bone metastasis, osteomyolysis, osteoarthritis, etc., which have pathological features similar to those at the high turnover sites in young healthy *BALB/c* mice. Further investigation is also needed to determine if the delivery system would provide similar targeting efficiency *in* models of osteoporosis and skeletal disease. The deposition pattern of the delivery system on the osteoporotic skeleton will be of particular interests.

Clearly, the targeting moiety (Tyr-D-Asp₈) possessed the best bone-selectivity among all the compounds tested. Besides bone, it showed a very low level in all the other tissues and organs. The absolute deposition amount to the skeleton was also very good. Using a L-Asp₆ conjugate with estradiol, Yokogawa et al. demonstrated the therapeutic benefit of the peptide.¹⁹ However, as the authors also noted, each peptide could only carry one drug molecule in their design. Further, the mechanism of drug release seems solely dependent on the degradation of L-Asp₆. In contrast to the peptide carrier, HPMA copolymer-D-Asp₈ conjugates could incorporate multiple drug molecules onto a single polymer chain. Various drug releasing mechanisms (pH or specific enzyme trigger) may also be employed for optimized drug release profile.⁷ However, the selectivity of HPMA copolymer-D-Asp₈ conjugates towards the hard tissue needs to be improved. P-D-Asp₈ (24 kDa) showed a relatively high deposition to kidneys, in addition to the skeleton, in agreement with results observed by Ghandehari's laboratory.²⁰ Potential re-absorption of the conjugate by epithelial cells of the kidneys via endocytosis may contribute to this observation.²¹ However, it is not clear why P-D-Asp₈ (24 kDa) showed a higher retention than P-D-Asp₈ (46 kDa) in kidneys. For high molecular weight P-D-Asp₈ (96 kDa), its long circulating half-life enhanced its deposition to the bone. But its distribution to the well-perfused organs, especially liver and spleen, was also evident (Figures 2 and 3). The *clustered* negative charges from the targeting moiety may be another contributing factor to this higher deposition (than non-targeted HPMA copolymer), as negatively charged macromolecules may be recognized by scavenger receptors on nonparenchymal cells.^{22,23} The reticuloendothelial system (RES) including macrophages, Kupffer cells of liver, reticulocytes of spleen and bone marrow may contribute to the deposition of non-targeted HPMA copolymers to soft tissues and the bone.²¹ Previous histomorphometric findings indicated that the retention sites of non-targeted HPMA copolymer in bone were only seen at the lining of marrow sinusoids, while the bone surface does not have any detectable deposition

(Figure 5). Depending on the therapeutic agents to be used, the inadequate distribution of the delivery system to soft tissues may cause significant side effects in vivo. Apparently, further optimization of the HPMA copolymer-D-Asp₈ conjugates to reduce their distribution to soft tissues is necessary.

Based on the above discussion, the following measures to improve the performance of the delivery system are being proposed. First, a polymer conjugate with molecular weight lower than the renal filtration threshold should be used as such conjugates will eventually be cleared from the body, limiting their deposition to the soft tissues and organs. Their accumulation in the kidneys must, however, be carefully monitored. The lower molecular weight will also lead to a shorter $\alpha T_{1/2}$ and allow a faster access of the delivery system to the bone. Second, the content of D-Asp₈ in the conjugate should be increased. Such improvement will enhance the binding force of the conjugate to bone. Since the binding efficiency depends on the competition between bone binding and renal clearance, a stronger binding force of the conjugate to bone would increase the first pass deposition to bone and increase the overall conjugate deposition to the skeleton. However, the current approach of using a D-Asp₈-containing macromonomer to incorporate the targeting moiety is not very effective. The content of D-Asp₈ in the conjugate is difficult to control, as evident from Table 1. Polymer-analogous reactions are being investigated to enhance the D-Asp₈ content in the conjugates. As a third potential, a high molecular weight (> 45 kDa) but biodegradable polymer carrier may provide a high deposition of the delivery system to the skeleton but also avoid its accumulation in the soft tissues. However, the degradation of the delivery system and its bone-binding process must be well orchestrated to yield an ideal biodistribution profile.

CONCLUSIONS

The biodistribution and pharmacokinetic data support the hypothesis that HPMA copolymer-D-Asp₈ conjugates can target to all parts of the skeleton. While increases of the molecular weight of the copolymer may raise the overall conjugate distribution to bone, the selectivity of the delivery system is reduced. Further fine-tuning of the conjugate structure is necessary to optimize its bone-targeting ability. In addition, validation of the delivery system in animal models of osteoporosis and other skeletal diseases is also warranted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We thank Dr. H. E. Gendelman for valuable discussion and for the permission to use the single photon emission computed tomography equipment. We also thank Dr. Huaiyun Han's technical support in part of the animal experiments. Dr. Dong Wang deeply appreciates the financial support he received as a new faculty from the College of Pharmacy, UNMC. This work was supported in part by NIH Grant GM069847.

ABBREVIATIONS USED

BD, biodistribution
 DMSO, dimethyl sulfoxide
 HOBt, 1-hydroxybenzotriazole hydrate
 HPMA, *N*-(2-hydroxypropyl)methacrylamide
 MA-FITC, *N*-methacryloylaminopropyl fluorescein thiourea
 MA-Gly-Gly-OH, *N*-methacryloylglycylglycine
 MA-Tyr-NH₂, *N*-methacryloyltyrosineamide
 M_n, number average molecular weight
 M_w, weight average molecular weight

P, tyrosine-labeled HPMA copolymer backbone
 P-D-Asp₈, tyrosine-labeled HPMA copolymer – D-Asp₈ conjugate
 PDI, polydispersity
 PK, pharmacokinetics
 PyBOP, benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
 SEC, size exclusion chromatography
 SPECT, single photon emission computed tomography
 SPPS, solid phase peptide synthesis
 T_{1/2}, elimination half-life
 Vd_{ss}, steady-state volume of distribution

REFERENCES

- Burckhardt P, Christiansen C, Fleisch HA. Consensus Development Conference: Prophylaxis and Treatment of Osteoporosis. *Am. J. Med* 1991;90:107–110. [PubMed: 1986575]
- National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. 2002. p. 1-16.
- O'Dell JR. Therapeutic strategies for rheumatoid arthritis. *N. Engl. J. Med* 2004;350:2591–2602. [PubMed: 15201416]
- Firestein, GS. Etiology and Pathogenesis of Rheumatoid Arthritis.. In: Harris, ED., Jr.; Budd, RC.; Genovese, MC.; Firestein, GS.; Sargent, JS.; Sledge, CB., editors. *Kelley's Textbook of Rheumatology*. 7th ed.. Elsevier Saunders; Philadelphia: 2005. p. 996
- Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis - an untreatable disease? *Nat. Rev. Drug Discov* 2005;4:331–344. [PubMed: 15803196]
- Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. *Science* 2000;289:1508–1514. [PubMed: 10968781]
- Wang D, Miller SC, Kopeček J. Drug delivery for musculoskeletal diseases: Challenges and opportunities. *Adv. Drug Deliv. Rev* 2005;57:935–937. [PubMed: 15876395]
- Wang D, Miller SC, Sima M, Kopečková P, Kopeček J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. *Bioconjug. Chem* 2003;14:853–859. [PubMed: 13129387]
- Pan HZ, Kopečková P, Wang D, Yang J, Miller SC, Kopeček J. Water-Soluble HPMA Copolymer – Prostaglandin Conjugates Containing a Cathepsin K Sensitive Spacer. *J. Drug Targeting*. in press
- Wang D, Miller SC, Sima M, Kopečková P, Kopeček J. Development of polymeric drug delivery systems that can differentially target bone formation and resorption surfaces. *J. Bone Miner. Res* 2005;20:S413.
- Kopeček J, Bažilová H. Poly[N-(2-hydroxypropyl)methacrylamide]. 1. Radical polymerization and copolymerization. *Eur. Polym. J* 1973;9:7–14.
- Omelyanenko V, Kopečková P, Gentry C, Kopeček J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. *J. Contr. Rel* 1998;53:25–37.
- Rejmanová P, Labský J, Kopeček J. Aminolyses of monomeric and polymeric pnitrophenyl esters of methacryloylated amino acids. *Makromol. Chem* 1977;178:2159–2168.
- Duncan R, Cable HC, Rejmanová P, Kopeček J, Lloyd JB. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. *Biochim. Biophys. Acta* 1984;799:1–8. [PubMed: 6722178]
- Chan, WC.; White, PD. *Fmoc Solid Phase Peptide Synthesis, A Practical Approach*. Oxford University Press; New York: 2000. p. 41-74.
- Kopeček J. Soluble biomedical polymers. *Polim. Med* 1977;7:191–221. [PubMed: 593972]
- Kopeček J, Kopečková P, Minko T, Lu Z-R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. *Eur. J. Pharm. Biopharm* 2000;50:61–81. [PubMed: 10840193]
- Seymour LW, Duncan R, Strohalm J, Kopeček J. Effect of molecular weight (M_w) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after

- subcutaneous, intraperitoneal, and intravenous administration to rats. *J. Biomed. Mater. Res* 1987;21:1341–1358. [PubMed: 3680316]
19. Yokogawa K, Miya K, Sekido T, Higashi Y, Nomura M, Fujisawa R, Morito K, Masamune Y, Waki Y, Kasugai S, Miyamoto K. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. *Endocrinology* 2001;142:1228–1233. [PubMed: 11181539]
20. Mitra A, Nan A, Ghandehari H, McNeill E, Mulholland J, Line BR. Technetium-99m-Labeled N-(2-hydroxypropyl)methacrylamide copolymers: Synthesis, characterization, and in vivo biodistribution. *Pharm. Res* 2004;21:1153–1159. [PubMed: 15290854]
21. Drobnik J, Rypáček F. Soluble synthetic polymers in biological systems. *Adv. Polym. Sci* 1984;57:1–50.
22. Yoshida M, Mahato RI, Kawabata K, Takakura Y, Hashida M. Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. *Pharm. Res* 1996;13:599–603. [PubMed: 8710753]
23. Fujiwara M, Baldeschwieler JD, Grubbs RH. Receptor-mediated endocytosis of poly(acrylic acid)-conjugated liposomes by macrophages. *Biochim. Biophys. Acta* 1996;1278:59–67. [PubMed: 8611608]

Figure 1.
Structure of Tyr-labeled HPMA copolymer - D-Asp₈ conjugates and of the peptide Tyr-D-Asp₈.

Figure 2.

Effect of molecular weight on the biodistribution of Tyr-labeled HPMA copolymer - D-Asp₈ conjugates (P-D-Asp₈). HPMA copolymers (no peptide) and Tyr-D-Asp₈ were used as controls. The ¹²⁵I-labeled samples were administered intravenously to *BALB/c* mice and the biodistribution analyzed at time intervals indicated. (A) 15 min, (B) 30 min, (C) 1 h, (D) 4 h, (E) 24 h. $P < 0.05$ except for P-D-Asp₈ (24 kDa and 46 kDa) in the kidneys and bone of (C); (F) 24 h – comparison of targeted and non-targeted conjugates. *T/Fx2* represents two sets of tibia and femur. The accumulation in the bone was significantly higher ($p < 0.05$) for all three P-D-Asp₈ as compared to their respective P_{control}. The targeting strategy did not result in significantly higher accumulation in any of the other organs with any of the different molecular weight conjugates except for P-D-Asp₈ 96 kDa, which showed a significantly higher accumulation in the liver and spleen as compared to P_{control} of the similar molecular weight.

Figure 3. Planar and tomographic images of *BALB/c* mice 24 h after i.v. administration of Tyr-labeled HPMA copolymer – D-Asp₈ conjugates and of Tyr-D-Asp₈ recorded by single photon emission computed tomography.

Figure 4. Blood clearance of ^{125}I -labeled HPMA copolymer-D-Asp₈ conjugates after intravenous administration to *BALB/c* mice. Radioactivity in the bloodstream (% injected dose) is shown for conjugates of different molecular weight and for Tyr-D-Asp₈.

Figure 5.

Histomorphometric analysis of long bones from BALB/c mice intravenously injected with P_{control}-FITC ($M_w = 68$ kDa, PDI = 1.5, [FITC] = 1.14×10^{-4} mol/g) and P-D-Asp₈-FITC ($M_w = 68$ kDa, PDI = 1.5, [D-Asp₈] = 1.77×10^{-4} mol/g, [FITC] = 1.05×10^{-4} mol/g). (1) Section through the mid-diaphyseal shaft illustrating the retention of the P_{control}-FITC in the marrow sinusoids (arrows); (2) Section through the mid-diaphyseal shaft illustrating the uptake of P-D-Asp₈-FITC on the endocortical surface (arrows). B = bone, M = marrow. Magnification 15 $\times$.

TABLE 1

Compounds used in the PK/BD study

#	Compound	M _w (kDa)	PD ^a	[D-Asp ₈] (mol/g)	D-Asp ₈ per macromolecule
1	Tyr-D-Asp ₈	1.1	1.00	-	-
2	P ^d -D-Asp ₈	24	1.07	1.84×10 ⁻⁴	4.4
3	P ^d -D-Asp ₈	46	1.07	1.21×10 ⁻⁴	5.6
4	P ^d -D-Asp ₈	96	1.06	1.00×10 ⁻⁴	9.6
5	P _{control}	23	1.03	-	-
6	P _{control}	42	1.16	-	-
7	P _{control}	105	1.17	-	-

^a P is the Tyr-labeled HPMA copolymer backbone

^b polydispersity (M_w/M_n)

TABLE 2

Pharmacokinetic parameters for tested compounds with different M_w

Compound	AUC (%dose/mL×h)	α $T_{1/2}$ (h)	β $T_{1/2}$ (h)	CL (mL/h)	MRT (h)	Vd_{ss} (mL)
Tyr-D-Asp ₈	8.04	0.11	24.95	12.43	29.70	369.13
p ^α -D-Asp ₈ (24 kDa)	3.21	0.69	8.74	31.16	10.04	312.75
p ^α -D-Asp ₈ (46 kDa)	60.18	0.90	11.77	1.66	11.11	18.45
p ^α -D-Asp ₈ (96 kDa)	978.41	4.62	41.28	0.10	52.57	5.37

^αP is the Tyr-labeled HPMA copolymer backbone